We are encouraged by USNA's better-than-expected sales in 4Q:25, which exceeded our expectations by about $5 million, prompting us to boost our EPS forecast by $0.01 to $0.41. Even more encouraging is the company's higher-than-expected revenue outlook for 2026, with USNA saying it expects revenue of $925 million to $1.0 billion, ahead of our previous forecast of $905.4 million. Most of the upside is from Rise Wellness, a rapidly growing third segment for USNA, in addition to the core nutritional supplement direct business and Hiya. As we raise our 2026 and 2027 revenue estimates and adjust our margin forecasts, we increase our 2026 and 2027 EPS estimates by $0.05 each year to $1.95 and $2.81, respectively. Our $39 price target is based on 14x our increased 2027 EPS estimate of $2.81 (was $2.76). Our moderate risk rating on USNA factors in the company's strong balance sheet and good free cash flow generation.